CPAP Improving Mortality for Pneumonia in African Children Trial

Pneumonia Clinical Trial

— IMPACT  

Official title:

Effectiveness of Bubble Continuous Positive Airway Pressure (CPAP) in Reducing Childhood Pneumonia Mortality in Malawi

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02484183
• Other study ID #: IRB00055734
• Status: Terminated
• Phase: N/A
• Start date: June 23, 2015
• Est. completion date: April 28, 2018

Study information

• Verified date: May 2018
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pneumonia mortality rates in African countries like Malawi are high and increased further in children -exposed or infected with human immunodeficiency virus (HIV) as well as those that are severely malnourished or severely hypoxemic. Treatment innovations are needed. Bubble continuous positive airway pressure (bCPAP) improves oxygenation and ventilation and is a simple, relatively inexpensive adaptation of conventional continuous positive airway pressure potentially suitable for low-resource settings. bCPAP has been demonstrated to improve outcomes in neonates less than 1 month of age. Recently, a limited number of hospitals are using bCPAP to escalate pneumonia care for older African children failing standard treatment with antibiotics and oxygen. Supportive evidence for this approach is observational only. Quality randomized studies comparing bCPAP versus a standard-of-care control group that includes low-flow oxygen therapy and using a primary endpoint of mortality are not available in low-resource settings including high prevalence HIV countries like Malawi. Demonstrating a mortality benefit with bCPAP is needed to support further investment and scale up of bCPAP in the care of older Malawian children 1-59 months of age with World Health Organization (WHO) severe pneumonia complicated by HIV and/or malnutrition or severe hypoxemia.

With the full support of the Malawi Ministry of Health and in collaboration with external experts from Lilongwe Medical Relief Trust and Cincinnati Children's Hospital Medical Center investigators plan to address this critical evidence gap by conducting a randomized controlled study determining bCPAP outcomes, compared to the currently recommended standard of care endorsed by the WHO and Malawi national pneumonia guidelines, in hospitalized Malawian children with WHO-defined severe pneumonia complicated by a co-morbidity ((1) HIV-infection, (2) HIV-exposure without infection, (3) severely malnourished) or WHO pneumonia with severe hypoxemia and without a co-morbidity. The investigators hypothesize that bCPAP will reduce the mortality of Malawian children with WHO-defined severe pneumonia.

Description:

Despite laudable reductions in global childhood mortality rates, pneumonia remains the second most frequent killer of children less than five years old worldwide. Nearly one million children succumbed to pneumonia in 2013, with greater than half of these deaths in Africa. In Malawi, which has a high prevalence of malnutrition and Human Immunodeficiency Virus (HIV) infection, pneumonia is a major cause of pediatric mortality. In patients with World Health Organization (WHO)-defined severe pneumonia, malnutrition, HIV-infection, and hypoxemia are the primary drivers of poor outcomes. In a recent analysis of 2001-2012 child pneumonia outcomes in Malawi the overall case fatality rate decreased from 15% to 4% except in children with severe malnutrition. The pneumonia mortality rate in malnourished children remained elevated at 15% despite antibiotics and increased access to supportive interventions like low-flow supplemental oxygen. In Malawian children with HIV-infection, WHO very severe pneumonia and severe malnutrition were the strongest predictors of death. Severe hypoxemic pneumonia may be as common in children as HIV-affected or severely malnourished cases, and may also have higher mortality than non HIV-affected, non-severely malnourished cases without severe hypoxemia. Non-invasive ventilation, already routinely used in industrialised countries, may provide an advanced treatment solution for certain patient populations such as children with WHO severe pneumonia complicated by severe malnutrition and/or HIV-infection or -exposure or severe hypoxemia.

Bubble continuous positive airway pressure (bCPAP) is non-invasive and is widely used for preterm neonatal respiratory failure in industrialised countries. Along with a flow generator, bCPAP uses a water column to deliver continuous positive pressure to a spontaneously breathing child. bCPAP is relatively inexpensive and requires little technical expertise compared with mechanical ventilation, but there is limited experience of bCPAP in resource-poor settings. Recently, small studies have explored its use in preterm neonates in Malawi. However, few studies have described its use in older infants and children, none of which included mortality as a primary endpoint and specially focused on the main drivers of poor pediatric pneumonia outcomes in southern Africa, HIV, malnutrition, and hypoxemia.

The investigators data using bCPAP in Malawian children with severe pneumonia suggest feasibility for implementation. The investigators have previously reported that using a bCPAP system derived from locally available, relatively inexpensive supplies has shown promise in the management of hospitalized HIV-infected children with pneumonia in Malawi. The investigators observational case series further delineates the outcomes of 77 Malawian children hospitalized at a tertiary referral facility with severe pneumonia who were treated with bCPAP. Nearly half were infants either infected or exposed to HIV or were severely malnourished. Although the mortality of this series of patients was 50.0%, bCPAP was initiated in this cohort only when patients were found to be failing standard treatment. The investigators estimated that more than 75% of these children would have been eligible for mechanical ventilation. In this proposed study the investigators will be initiating bCPAP earlier in the hospitalization prior to treatment failure. Unlike previous studies conducted at referral hospitals, the investigators will perform this study at the district hospital level where 80% of hospitalized child pneumonia cases are cared for in Malawi.

Although bCPAP is relatively inexpensive, scale-up in countries like Malawi with significant pneumonia burden and high HIV prevalence will require substantial resources to meet expected needs. In order to appropriately allocate precious resources and provide practical clinical guidance for healthcare providers who may use bCPAP, it is paramount to fully understand the utility of bCPAP treatment in this setting. To the investigators knowledge no bCPAP data using a control group with mortality as the primary outcome has been reporting in a similar generalized HIV epidemic African patient population 1-59 months of age. Data generated from this research will be additionally critical for formulating future studies that may include bCPAP refinements or exploration of other feasible modalities like high-flow nasal cannula or bi-level positive airway pressure. Therefore, the more rigorous methodology proposed here is warranted and supported by the Malawi Ministry of Health. If bCPAP proves an effective treatment modality for children hospitalized with WHO severe pneumonia, it is a simple technology that could be operationalized to help thousands of children with life-threatening pneumonia.

The investigators propose to address this critical evidence gap by conducting a randomized controlled study determining bCPAP outcomes, compared to the currently recommended standard of care endorsed by the WHO and Malawi Ministry of Health, in hospitalized Malawian children with WHO-defined severe pneumonia complicated by malnutrition and/or HIV-infection or -exposure, or severe hypoxemia.

RATIONALE

Quality randomized studies comparing bCPAP versus a standard-of-care control group that includes low-flow oxygen therapy and using a primary endpoint of mortality are not available in low-resource settings including high prevalence HIV countries like Malawi for children 1-59 months of age with severe pneumonia. Demonstrating a mortality benefit with bCPAP is needed to support further investment and scale up of bCPAP in the care of older Malawian children 1-59 months of age with World Health Organization (WHO) severe pneumonia complicated by HIV and/or malnutrition, or severe hypoxemia.

STUDY HYPOTHESIS AND OBJECTIVES

• Study Hypotheses

The investigators hypothesize that bCPAP, compared to standard care, will reduce the mortality of Malawian children with WHO-defined severe pneumonia complicated by a severe co-morbidity (HIV-infection or HIV-exposure and/or severe malnutrition), or severe hypoxemia without a severe co-morbidity.

• Study Objectives

The broad objective of this study is to provide scientific evidence assessing the effectiveness of treatment with bCPAP for WHO severe childhood pneumonia for children 1-59 months of age in Malawi, Africa.

• Primary Objective 1

• Determine the pneumonia mortality rate for bCPAP treatment, compared to standard of care, for children with WHO severe pneumonia.

• Primary Objective 2

• Determine the pneumonia mortality rate for bCPAP treatment, compared to standard of care, for children with WHO severe hypoxemic pneumonia without co-morbidity (i.e., no HIV infection, no HIV-exposure, no severe malnutrition).

• Primary Objective 3

• Determine the pneumonia mortality rate for bCPAP treatment, compared to standard of care, for children with WHO severe pneumonia and co-morbidity (i.e., HIV-infection or HIV-exposure and/or severe malnutrition).

• Secondary Objectives

• Determine the pneumonia day 14 treatment failure rate for bCPAP treatment, compared to standard of care, for HIV-infected children with WHO severe pneumonia.

• Determine the pneumonia day 14 treatment failure rate for bCPAP treatment, compared to standard of care, for HIV-exposed, uninfected children with WHO severe pneumonia.

• Determine the pneumonia day 14 treatment failure rate for bCPAP treatment, compared to standard of care, for severely malnourished children with WHO severe pneumonia.

• Determine the pneumonia day 14 treatment failure rate for bCPAP treatment, compared to standard of care, for severely hypoxemic children with WHO severe pneumonia.

• Determine the proportion of children alive at day 30 phone follow up.

• To investigate whether there may be differential treatment responses in certain baseline characteristics including but not limited to children with severe anemia, in those who test positive for malaria, in those with wheeze at baseline, in those with altered mental status, in those with digital auscultation-defined lung disease, and whether there is a differential treatment response by age.

• To determine whether intervention arms have equivalent rates of adverse events as control arms.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 646
• Est. completion date: April 28, 2018
• Est. primary completion date: April 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 59 Months

Eligibility

Inclusion Criteria:

• Meets World Health Organization (WHO) severe pneumonia criteria and is either Human Immunodeficiency Virus (HIV)-infected, HIV-exposed, severely malnourished, or has severe hypoxemia without HIV-infection, HIV-exposure, or severe malnutrition.

Exclusion Criteria:

• Any psychosocial condition or circumstance that, in the opinion of the investigators, would interfere with the conduct of the study. Prior participation in the study during a previous pneumonia diagnosis.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Human Immunodeficiency Virus (HIV)
• Hypoxemia
• Hypoxia
• Immunologic Deficiency Syndromes
• Malnutrition
• Pneumonia

Intervention

Device:
• bubble continuous positive airway pressure (CPAP)
This study will use an Airsep® oxygen concentrator and a Fisher & Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer & Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer & Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.

Locations

Country	Name	City	State
Malawi	Salima District Hospital	Salima

Sponsors (5)

Lead Sponsor	Collaborator
Johns Hopkins University	Children's Hospital Medical Center, Cincinnati, Ministry of Health and Population, Malawi, University of North Carolina, Chapel Hill, University of Utah

Country where clinical trial is conducted

Malawi, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pneumonia mortality	Proportion of in-hospital death in children with World Health Organization (WHO) severe pneumonia.	Participants followed for duration of hospital stay, an expected average of 7 days
Secondary	Post-discharge mortality	Overall mortality 30 days after discharge.	30 days after hospital discharge.
Secondary	Relapse	Proportion of children with a pneumonia cure but relapsed before day 30.	30 days
Secondary	Treatment failure	Proportion of children failing treatment by day 14.	14 days